



Vivimed

Investor Release

Vivimed - Strides Shasun JV to launch Ranitidine OTC tables in US markets

Hyderabad, India, February 26, 2018 – Vivimed Labs Limited and Strides Shasun JV announced today that it has received its first product approval **Ranitidine tablet USP, 150 mg (OTC)** and will be launched in the US markets. As per the IRI data, the US OTC market for Ranitidine tablets, which is a generic form of the popular brand is Zantac, is approximately USD 200 million.

The product will be manufactured at JV's oral dosage manufacturing facility in Chennai. The product will be launched in the US markets immediately.

Ranitidine belongs to a class of drugs known as H2 histamine blockers. It is used to treat peptic ulcers of the stomach and intestines and gastroesophageal reflux and heartburn related to indigestion.

Commenting on the development, **Mr. Sandeep Varalwar, Executive Director** said:

“The product approval is a very encouraging scenario and we expect further approvals during the year. The relationship with Strides Shasun will go a long way in capitalising the opportunity in US.”

Mr Sandeep further commented that Vivimed has an interesting pipeline of complex generic formulations for FY 20

About Vivimed Labs:

Vivimed is a Pharmaceuticals and Specialty Chemicals company headquartered in Hyderabad, India. It has manufacturing footprint across India, Europe and North America across its line of business and employs close to 2000 personnel across the world. Vivimed reported sales of about INR 15 bn for the financial year ended March 31, 2017.

For further information on Vivimed, visit www.vivimedlabs.com

*** **

For VIVIMED LABS LTD.


Company Secretary



Vivimed

Safe Harbour

This release contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed’s future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information please contact	
<u>Company Contact:</u> Vivimed Labs Limited CIN No: L02411KA1988PLC009465 Sunil Arab Email: sunil.arab@vivimedlabs.com B. Rajaprasad Email: Rajaprasad.B@vivimedlabs.com	<u>Investor Relations:</u> Strategic Growth Advisors Pvt Ltd. CIN No: U74140MH2010PTC204285 Rahul Agarwal Email: rahul.agarwal@sgapl.net Tel No: +91 79770 90416

For VIVIMED LABS LTD.


Company Secretary